Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients - Archive ouverte HAL Access content directly
Journal Articles European Journal of Clinical Microbiology and Infectious Diseases Year : 2021

Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients

(1) , (2) , (1) , (3, 4) , (3, 4) , (3, 4) , (5, 6) , (5, 6) , (5, 6) , (4) , (4) , (4) , (7) , (7) , (7) , (7) , (8) , (8) , (9) , (10) , (10) , (10) , (10) , (11) , (11) , (11) , (11) , (11) , (12) , (12) , (13) , (13) , (10) , (10) , (10) , (2) , (2) , (2) , (1) , (14) , (14) , (14) , (1) , (10) , (7)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Flore Rozenberg
Véronique Avettand-Fenoel
Elise Gardiennet
  • Function : Author
Juliette Villemonteix

Abstract

We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.

Dates and versions

inserm-03227584 , version 1 (17-05-2021)

Identifiers

Cite

Christelle Vauloup-Fellous, Sarah Maylin, Claire Périllaud-Dubois, Ségolène Brichler, Chakib Alloui, et al.. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. European Journal of Clinical Microbiology and Infectious Diseases, 2021, Online ahead of print. ⟨10.1007/s10096-021-04232-3⟩. ⟨inserm-03227584⟩
48 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More